Latest News — Page 11

Artificial Intelligence And Machine Learning
UK AI Healthcare Commission Report Calls for L-Plates Regulation
An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess

Artificial Intelligence And Machine Learning
AI in Portuguese Healthcare: What Should Portugal Want It to Do?
Nova SBE’s Saúde em Perspetiva podcast asks what Portugal’s National Health Service should want from AI, and where the red lines sit. #SyenzaNews #DigitalHealth #AIinHealthcare

Biologics And Biosimilars
Sandoz Bio100 Biosimilars Plan Targets 100 Products by 2040
Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

Clinical Practice
Semaglutide Linked to Fewer Asthma Attacks in UK Data
Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Clinical Practice
FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Breast Cancer
Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

Diseases
South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP
South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme’s first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Diseases
Novartis and The Max Foundation Mark 25 Years of Cancer Access in LMICs
Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding.
#SyenzaNews #MarketAccess #GlobalHealth

Clinical Practice
Six Proteomic Aging Clocks Detect Age Reversal With Rentosertib
An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Cardiovascular And Metabolic Diseases
Novo Nordisk Halts Ziltivekimab Heart Failure Trials
Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Clinical Practice
Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP
Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck’s once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Diabetes
Aspen Pharmacare Bets on Manufacturing Rebound and Generic Semaglutide
Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

Clinical Practice
Trump’s MFN Drug Pricing Policy Is Cutting Europe’s Access to New Medicines
Trump’s Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

Clinical Practice
Medicare GLP-1 Bridge Tops 500,000 Users in Its First Two Months
US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare

Clinical Practice
EMA Pre-Submission Pilot Adds Earlier Dialogue to Curb Premature Filings
EMA’s voluntary pre-submission pilot opens in September 2026. It adds earlier, more structured dialogue between applicants, rapporteurs and the Agency to curb premature filings. #SyenzaNews #MarketAccess #RegulatoryAffairs

Diseases
Autoimmune CAR-T Safety Test Emerges After Trial Pauses
Novartis and Bristol Myers Squibb have paused autoimmune CAR-T trials after inflammatory events and three deaths, putting the immune-reset thesis to its first real safety test. #SyenzaNews #CellTherapy #AutoimmuneDisease #MarketAccess

Clinical Practice
US healthcare market access: what four operators told Canadian healthtech founders
CTS’s Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech

